{
    "info": {
        "nct_id": "NCT03711058",
        "official_title": "A Phase I/II Study of PI3Kinase Inhibition (Copanlisib) and Anti-PD-1 Antibody Nivolumab in Relapsed/Refractory Solid Tumors With Expansions in Mismatch-repair Proficient (MSS) Colorectal Cancer",
        "inclusion_criteria": "* Age ≥18 years.\n* Ability to understand and willingness to sign a written informed consent document.\n* Phase I: Must have received all curative treatment options and at least 2 lines of systemic therapy.\n* Phase II: Must have received at least 2 lines of systemic therapy including a fluoropyrimidine, oxaliplatin, and irinotecan-containing regimen. KRAS/NRAS/BRAF wildtype patients must have received or refused anti-EGR.\n* Must have received all curative treatment options and at least 2 lines of systemic and standard therapy.\n* Must have measurable disease based on RECIST 1.1\n* Must have biopsiable disease.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1\n* Life expectancy of greater than 3 months.\n* Patients must have adequate organ and marrow function defined by study-specified laboratory tests within 21 days of initial study drug.\n* Men must use acceptable form of birth control while on study.\n* Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1, anti- PD-L2, anti-CTLA4, etc.).\n* Prior therapy with a PI3K inhibitor\n* Chemotherapy, target small molecule therapy, investigational therapy, or surgery within 4 weeks prior to first dose of treatment.\n* Has received prior radiotherapy within 2 weeks prior to the start of treatment.\n* Patient who is receiving or have received any other investigational agents within 4 weeks prior to the first dose of treatment.\n* Has received a live vaccine 30 days prior to the first dose of study drug.\n* Has known additional malignancy that is progressing or requires active treatment..\n* Has known central nervous system (CNS) metastases and/or carcinomatous meningitis.\n* Has symptomatic ascites or has required a paracentesis in the last 12 weeks.\n* Hypersensitivity reaction to study drug.\n* Patients diagnosed of immunodeficiency or are on any immunosuppressive agents within 7 days prior to first dose of study drug.\n* Has active autoimmune disease that has required systemic treatment in the past 12 months, or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents.\n* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.\n* Has an active infection requiring systemic therapy.\n* Infection with HIV or hepatitis B or C.\n* Cytomegalovirus polymerase chain reaction (CMV PCR) positive.\n* Known history or concurrent interstitial lung disease.\n* Type I diabetes or Type II diabetes requiring treatment with a sulfonylurea, meglitinide, or insulin at screening.\n* Uncontrolled cardiovascular disease.\n* Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.\n* Use of anti-arrhythmic therapy (beta blockers or digoxin are permitted).\n* Use of CYP3A4 inhibitors and inducers within 2 weeks of starting study drug and throughout treatment.\n* Any arterial or venous thrombotic or embolic events within 3 months of start of study drug.\n* Non-healing wound, ulcer, or fracture.\n* Patients with evidence or history of bleeding condition.\n* Had a blood or platelet transfusion within 7 days of Cycle 1 Day 1 treatment.\n* Seizure disorder requiring anti-seizure medication.\n* Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures.\n* Are pregnant or breastfeeding.\n* Unwilling or unable to follow the study schedule for any reason.",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* Age ≥18 years.",
            "criterions": [
                {
                    "exact_snippets": "Age ≥18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Ability to understand and willingness to sign a written informed consent document.",
            "criterions": [
                {
                    "exact_snippets": "Ability to understand",
                    "criterion": "cognitive ability to understand informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign a written informed consent document",
                    "criterion": "willingness to sign informed consent",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Phase I: Must have received all curative treatment options and at least 2 lines of systemic therapy.",
            "criterions": [
                {
                    "exact_snippets": "Must have received all curative treatment options",
                    "criterion": "curative treatment options",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 2 lines of systemic therapy",
                    "criterion": "systemic therapy lines",
                    "requirements": [
                        {
                            "requirement_type": "number of lines received",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Phase II: Must have received at least 2 lines of systemic therapy including a fluoropyrimidine, oxaliplatin, and irinotecan-containing regimen. KRAS/NRAS/BRAF wildtype patients must have received or refused anti-EGR.",
            "criterions": [
                {
                    "exact_snippets": "Must have received at least 2 lines of systemic therapy",
                    "criterion": "lines of systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "including a fluoropyrimidine, oxaliplatin, and irinotecan-containing regimen",
                    "criterion": "systemic therapy regimen components",
                    "requirements": [
                        {
                            "requirement_type": "inclusion",
                            "expected_value": [
                                "fluoropyrimidine",
                                "oxaliplatin",
                                "irinotecan"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "KRAS/NRAS/BRAF wildtype patients must have received or refused anti-EGR",
                    "criterion": "KRAS/NRAS/BRAF mutation status",
                    "requirements": [
                        {
                            "requirement_type": "mutation status",
                            "expected_value": "wildtype"
                        }
                    ]
                },
                {
                    "exact_snippets": "KRAS/NRAS/BRAF wildtype patients must have received or refused anti-EGR",
                    "criterion": "anti-EGR therapy",
                    "requirements": [
                        {
                            "requirement_type": "received or refused",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "KRAS/NRAS/BRAF wildtype patients"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must have received all curative treatment options and at least 2 lines of systemic and standard therapy.",
            "criterions": [
                {
                    "exact_snippets": "Must have received all curative treatment options",
                    "criterion": "curative treatment options",
                    "requirements": [
                        {
                            "requirement_type": "completion",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "at least 2 lines of systemic and standard therapy",
                    "criterion": "systemic and standard therapy",
                    "requirements": [
                        {
                            "requirement_type": "number of lines received",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "lines"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must have measurable disease based on RECIST 1.1",
            "criterions": [
                {
                    "exact_snippets": "Must have measurable disease based on RECIST 1.1",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_criteria",
                            "expected_value": "RECIST 1.1"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Must have biopsiable disease.",
            "criterions": [
                {
                    "exact_snippets": "Must have biopsiable disease.",
                    "criterion": "disease",
                    "requirements": [
                        {
                            "requirement_type": "biopsiable",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
            "criterions": [
                {
                    "exact_snippets": "Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Life expectancy of greater than 3 months.",
            "criterions": [
                {
                    "exact_snippets": "Life expectancy of greater than 3 months",
                    "criterion": "life expectancy",
                    "requirements": [
                        {
                            "requirement_type": "duration",
                            "expected_value": {
                                "operator": ">",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients must have adequate organ and marrow function defined by study-specified laboratory tests within 21 days of initial study drug.",
            "criterions": [
                {
                    "exact_snippets": "adequate organ and marrow function defined by study-specified laboratory tests within 21 days of initial study drug",
                    "criterion": "organ and marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "study-specified laboratory tests"
                        },
                        {
                            "requirement_type": "assessment_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 21,
                                "unit": "days before initial study drug"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Men must use acceptable form of birth control while on study.",
            "criterions": [
                {
                    "exact_snippets": "Men must use acceptable form of birth control while on study.",
                    "criterion": "male participants",
                    "requirements": [
                        {
                            "requirement_type": "use of acceptable birth control",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "while on study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Woman of childbearing potential must have a negative pregnancy test and follow contraceptive guidelines as defined per protocol.",
            "criterions": [
                {
                    "exact_snippets": "Woman of childbearing potential",
                    "criterion": "sex and reproductive status",
                    "requirements": [
                        {
                            "requirement_type": "sex",
                            "expected_value": "female"
                        },
                        {
                            "requirement_type": "childbearing potential",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "must have a negative pregnancy test",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "pregnancy test result",
                            "expected_value": "negative"
                        }
                    ]
                },
                {
                    "exact_snippets": "follow contraceptive guidelines as defined per protocol",
                    "criterion": "contraceptive use",
                    "requirements": [
                        {
                            "requirement_type": "adherence to contraceptive guidelines",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "* Patient who is receiving or have received any other investigational agents within 4 weeks prior to the first dose of treatment.",
            "criterions": [
                {
                    "exact_snippets": "receiving or have received any other investigational agents within 4 weeks prior to the first dose of treatment",
                    "criterion": "receipt of investigational agents",
                    "requirements": [
                        {
                            "requirement_type": "time since last receipt",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received prior radiotherapy within 2 weeks prior to the start of treatment.",
            "criterions": [
                {
                    "exact_snippets": "Has received prior radiotherapy within 2 weeks prior to the start of treatment.",
                    "criterion": "prior radiotherapy",
                    "requirements": [
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "weeks prior to the start of treatment"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Cytomegalovirus polymerase chain reaction (CMV PCR) positive.",
            "criterions": [
                {
                    "exact_snippets": "Cytomegalovirus polymerase chain reaction (CMV PCR) positive",
                    "criterion": "Cytomegalovirus polymerase chain reaction (CMV PCR)",
                    "requirements": [
                        {
                            "requirement_type": "result",
                            "expected_value": "positive"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has received a live vaccine 30 days prior to the first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Has received a live vaccine 30 days prior to the first dose of study drug.",
                    "criterion": "live vaccine administration",
                    "requirements": [
                        {
                            "requirement_type": "time since administration",
                            "expected_value": {
                                "operator": ">=",
                                "value": 30,
                                "unit": "days"
                            }
                        },
                        {
                            "requirement_type": "vaccine type",
                            "expected_value": "live"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has a history of (non-infectious) pneumonitis that required steroids or has current pneumonitis.",
            "criterions": [
                {
                    "exact_snippets": "history of (non-infectious) pneumonitis that required steroids",
                    "criterion": "(non-infectious) pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": "required steroids"
                        }
                    ]
                },
                {
                    "exact_snippets": "current pneumonitis",
                    "criterion": "pneumonitis",
                    "requirements": [
                        {
                            "requirement_type": "current presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Conditions, including alcohol or drug dependence, intercurrent illness, or lack of sufficient peripheral venous access, that would affect the patient's ability to comply with study visits and procedures.",
            "criterions": [
                {
                    "exact_snippets": "alcohol or drug dependence",
                    "criterion": "alcohol or drug dependence",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "intercurrent illness",
                    "criterion": "intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        }
                    ]
                },
                {
                    "exact_snippets": "lack of sufficient peripheral venous access",
                    "criterion": "peripheral venous access",
                    "requirements": [
                        {
                            "requirement_type": "sufficiency",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has an active infection requiring systemic therapy.",
            "criterions": [
                {
                    "exact_snippets": "Has an active infection requiring systemic therapy.",
                    "criterion": "active infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "requires systemic therapy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hypersensitivity reaction to study drug.",
            "criterions": [
                {
                    "exact_snippets": "Hypersensitivity reaction to study drug",
                    "criterion": "hypersensitivity reaction to study drug",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known history or concurrent interstitial lung disease.",
            "criterions": [
                {
                    "exact_snippets": "Known history ... interstitial lung disease",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "concurrent interstitial lung disease",
                    "criterion": "interstitial lung disease",
                    "requirements": [
                        {
                            "requirement_type": "concurrent presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of CYP3A4 inhibitors and inducers within 2 weeks of starting study drug and throughout treatment.",
            "criterions": [
                {
                    "exact_snippets": "Use of CYP3A4 inhibitors and inducers within 2 weeks of starting study drug and throughout treatment.",
                    "criterion": "use of CYP3A4 inhibitors",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Use of CYP3A4 inhibitors and inducers within 2 weeks of starting study drug and throughout treatment.",
                    "criterion": "use of CYP3A4 inducers",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2,
                                        "unit": "weeks"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Are pregnant or breastfeeding.",
            "criterions": [
                {
                    "exact_snippets": "Are pregnant",
                    "criterion": "pregnancy status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "breastfeeding",
                    "criterion": "breastfeeding status",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Type I diabetes or Type II diabetes requiring treatment with a sulfonylurea, meglitinide, or insulin at screening.",
            "criterions": [
                {
                    "exact_snippets": "Type I diabetes",
                    "criterion": "Type I diabetes",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Type II diabetes requiring treatment with a sulfonylurea, meglitinide, or insulin at screening",
                    "criterion": "Type II diabetes",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": [
                                "sulfonylurea",
                                "meglitinide",
                                "insulin"
                            ]
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unwilling or unable to follow the study schedule for any reason.",
            "criterions": [
                {
                    "exact_snippets": "Unwilling or unable to follow the study schedule for any reason",
                    "criterion": "ability and willingness to follow study schedule",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "ability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled cardiovascular disease.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled cardiovascular disease",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior therapy with a PI3K inhibitor",
            "criterions": [
                {
                    "exact_snippets": "Prior therapy with a PI3K inhibitor",
                    "criterion": "prior therapy with a PI3K inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients with evidence or history of bleeding condition.",
            "criterions": [
                {
                    "exact_snippets": "evidence or history of bleeding condition",
                    "criterion": "bleeding condition",
                    "requirements": [
                        {
                            "requirement_type": "evidence or history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Seizure disorder requiring anti-seizure medication.",
            "criterions": [
                {
                    "exact_snippets": "Seizure disorder requiring anti-seizure medication",
                    "criterion": "seizure disorder",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requiring anti-seizure medication",
                    "criterion": "anti-seizure medication",
                    "requirements": [
                        {
                            "requirement_type": "requirement for use",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1, anti- PD-L2, anti-CTLA4, etc.).",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with immunotherapy agents (including, anti-PD-1, anti-PD-L1, anti- PD-L2, anti-CTLA4, etc.)",
                    "criterion": "prior treatment with immunotherapy agents",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patients diagnosed of immunodeficiency or are on any immunosuppressive agents within 7 days prior to first dose of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Patients diagnosed of immunodeficiency",
                    "criterion": "immunodeficiency",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "are on any immunosuppressive agents within 7 days prior to first dose of study drug",
                    "criterion": "immunosuppressive agent use",
                    "requirements": [
                        {
                            "requirement_type": "use within time window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days prior to first dose of study drug"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Had a blood or platelet transfusion within 7 days of Cycle 1 Day 1 treatment.",
            "criterions": [
                {
                    "exact_snippets": "Had a blood or platelet transfusion within 7 days of Cycle 1 Day 1 treatment.",
                    "criterion": "blood transfusion",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to Cycle 1 Day 1",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Had a blood or platelet transfusion within 7 days of Cycle 1 Day 1 treatment.",
                    "criterion": "platelet transfusion",
                    "requirements": [
                        {
                            "requirement_type": "timing relative to Cycle 1 Day 1",
                            "expected_value": {
                                "operator": "<=",
                                "value": 7,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Use of anti-arrhythmic therapy (beta blockers or digoxin are permitted).",
            "criterions": [
                {
                    "exact_snippets": "Use of anti-arrhythmic therapy (beta blockers or digoxin are permitted)",
                    "criterion": "anti-arrhythmic therapy",
                    "requirements": [
                        {
                            "requirement_type": "use",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "exception",
                            "expected_value": [
                                "beta blockers",
                                "digoxin"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any arterial or venous thrombotic or embolic events within 3 months of start of study drug.",
            "criterions": [
                {
                    "exact_snippets": "Any arterial or venous thrombotic or embolic events within 3 months of start of study drug.",
                    "criterion": "arterial thrombotic or embolic events",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Any arterial or venous thrombotic or embolic events within 3 months of start of study drug.",
                    "criterion": "venous thrombotic or embolic events",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has known additional malignancy that is progressing or requires active treatment..",
            "criterions": [
                {
                    "exact_snippets": "Has known additional malignancy",
                    "criterion": "additional malignancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "that is progressing",
                    "criterion": "additional malignancy progression",
                    "requirements": [
                        {
                            "requirement_type": "progression",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "requires active treatment",
                    "criterion": "additional malignancy treatment requirement",
                    "requirements": [
                        {
                            "requirement_type": "active treatment requirement",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has symptomatic ascites or has required a paracentesis in the last 12 weeks.",
            "criterions": [
                {
                    "exact_snippets": "Has symptomatic ascites",
                    "criterion": "ascites",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has required a paracentesis in the last 12 weeks",
                    "criterion": "paracentesis",
                    "requirements": [
                        {
                            "requirement_type": "required_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has known central nervous system (CNS) metastases and/or carcinomatous meningitis.",
            "criterions": [
                {
                    "exact_snippets": "Has known central nervous system (CNS) metastases",
                    "criterion": "central nervous system (CNS) metastases",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "carcinomatous meningitis",
                    "criterion": "carcinomatous meningitis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Non-healing wound, ulcer, or fracture.",
            "criterions": [
                {
                    "exact_snippets": "Non-healing wound",
                    "criterion": "wound",
                    "requirements": [
                        {
                            "requirement_type": "healing status",
                            "expected_value": "non-healing"
                        }
                    ]
                },
                {
                    "exact_snippets": "Non-healing ... ulcer",
                    "criterion": "ulcer",
                    "requirements": [
                        {
                            "requirement_type": "healing status",
                            "expected_value": "non-healing"
                        }
                    ]
                },
                {
                    "exact_snippets": "Non-healing ... fracture",
                    "criterion": "fracture",
                    "requirements": [
                        {
                            "requirement_type": "healing status",
                            "expected_value": "non-healing"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Has active autoimmune disease that has required systemic treatment in the past 12 months, or a documented history of clinically severe autoimmune disease, or a syndrome that requires systemic steroids or immunosuppressive agents.",
            "criterions": [
                {
                    "exact_snippets": "Has active autoimmune disease that has required systemic treatment in the past 12 months",
                    "criterion": "active autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "systemic treatment requirement",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "treatment time frame",
                            "expected_value": {
                                "operator": "<=",
                                "value": 12,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "documented history of clinically severe autoimmune disease",
                    "criterion": "clinically severe autoimmune disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "severity",
                            "expected_value": "clinically severe"
                        }
                    ]
                },
                {
                    "exact_snippets": "syndrome that requires systemic steroids or immunosuppressive agents",
                    "criterion": "syndrome requiring systemic steroids or immunosuppressive agents",
                    "requirements": [
                        {
                            "requirement_type": "treatment requirement",
                            "expected_value": [
                                "systemic steroids",
                                "immunosuppressive agents"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Patient with uncontrolled intercurrent illness including, but not limited to, uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.",
            "criterions": [
                {
                    "exact_snippets": "uncontrolled infection",
                    "criterion": "infection",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "symptomatic congestive heart failure",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "symptomatic",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina pectoris",
                    "criterion": "angina pectoris",
                    "requirements": [
                        {
                            "requirement_type": "stability",
                            "expected_value": "unstable"
                        }
                    ]
                },
                {
                    "exact_snippets": "cardiac arrhythmia",
                    "criterion": "cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "psychiatric illness/social situations that would limit compliance with study requirements",
                    "criterion": "psychiatric illness or social situations limiting compliance",
                    "requirements": [
                        {
                            "requirement_type": "impact on compliance",
                            "expected_value": "would limit compliance with study requirements"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Chemotherapy, target small molecule therapy, investigational therapy, or surgery within 4 weeks prior to first dose of treatment.",
            "criterions": [
                {
                    "exact_snippets": "Chemotherapy ... within 4 weeks prior to first dose of treatment.",
                    "criterion": "chemotherapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "target small molecule therapy ... within 4 weeks prior to first dose of treatment.",
                    "criterion": "target small molecule therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "investigational therapy ... within 4 weeks prior to first dose of treatment.",
                    "criterion": "investigational therapy",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "surgery within 4 weeks prior to first dose of treatment.",
                    "criterion": "surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since last treatment",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Infection with HIV or hepatitis B or C.",
            "criterions": [
                {
                    "exact_snippets": "Infection with HIV",
                    "criterion": "HIV infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis B",
                    "criterion": "hepatitis B infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "hepatitis C",
                    "criterion": "hepatitis C infection",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": []
}